Abbott India Limited reported earnings results for the third quarter and nine months ended December 31, 2024. For the third quarter, the company reported sales was INR 16,142.8 million compared to INR 14,371.4 million a year ago. Revenue was INR 16,860.3 million compared to INR 14,927.5 million a year ago. Net income was INR 3,607.8 million compared to INR 3,109.8 million a year ago. Basic earnings per share from continuing operations was INR 169.78 compared to INR 146.34 a year ago.
For the nine months, sales was INR 48,045.6 million compared to INR 44,102.8 million a year ago. Revenue was INR 50,041.2 million compared to INR 45,774 million a year ago. Net income was INR 10,474 million compared to INR 9,141.6 million a year ago. Basic earnings per share from continuing operations was INR 492.89 compared to INR 430.19 a year ago.
Abbott India Limited is an India-based company engaged in the pharmaceuticals business. The Company is involved in product development, manufacturing, and sales of healthcare products. It operates in a single reportable business segment, which is Pharmaceuticals. It distributes products and solutions in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders, Central Nervous System, Vaccines, Multi-Specialty, and primary care. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), and Duvadilan (preterm labor). It offers various products under brands such as Similac, PediaSure, Pedialyte, EleCare, Ensure, and Glucerna.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
